Maxim Group Initiates Coverage On Telomir Pharmaceuticals with Buy Rating, Announces Price Target of $4

Maxim Group analyst Jason McCarthy has initiated coverage on Telomir Pharmaceuticals (NASDAQ: TELO) with a Buy rating. The firm has set a price target of $4 for the company's stock.